STAT+: RA Capital backs upstart rival to Ultragenyx and Ionis in rare brain disease

STAT News

Oak Hill Bio, a new company backed by RA Capital and other investors, will take on Ultragenyx and Ionis in developing an Angelman syndrome medicine. ...

전문 보기

이 뉴스, 어떠셨어요?

탭 한 번으로 반응 · 로그인 불필요

관련 뉴스

관련 뉴스 제보는 로그인 후 가능합니다.

'science' 카테고리 뉴스

STAT의 다른 기사

Opinion: E-bikes, e-scooters are a burgeoning pediatric public health emergency

STAT News

STAT+: As some medical schools embrace RFK Jr.’s nutrition push, they deftly sidestep MAHA priorities

STAT News

Opinion: How midwives like me can help fight medical misinformation

STAT News

STAT+: RA Capital backs upstart rival to Ultragenyx and Ionis in rare brain disease

이 뉴스, 어떠셨어요?

관련 뉴스

'science' 카테고리 뉴스

Could we send a spacecraft to a black hole?

Measuring more than recovery: New health care tool for older Australians

A trend that isn’t fading, ultra-processed baby foods

STAT의 다른 기사

Opinion: E-bikes, e-scooters are a burgeoning pediatric public health emergency

STAT+: As some medical schools embrace RFK Jr.’s nutrition push, they deftly sidestep MAHA priorities

Opinion: How midwives like me can help fight medical misinformation